24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, +43

The Lancet Neurology

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Daniela Bertens, Betty M. Tijms, Philip Scheltens, +2

Alzheimer s Research & Therapy

Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease

Daniela Bertens, Dirk L. Knol, Philip Scheltens, +1

Alzheimer s & Dementia

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

Daniela Bertens, Stephanie J. B. Vos, Patrick G. Kehoe, +10

Alzheimer s Research & Therapy

Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects

Betty M. Tijms, Daniela Bertens, Rosalinde E.R. Slot, +5

Annals of Neurology

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design

Daniela Bertens, Betty M. Tijms, Lisa Vermunt, +3

Alzheimer s & Dementia Translational Research & Clinical Interventions